Overview

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Status:
RECRUITING
Trial end date:
2026-12-24
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, Phase 3 study
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Kechow Pharma, Inc.
Treatments:
Vemurafenib